Synthetix Releases SIP-423 Proposal to Gradually Phase Out sUSD and Reform SNX Staking Mechanism
Foresight News reports that Synthetix core contributors Kain Warwick and Benjamin Celermajer have jointly submitted the SIP-423 proposal, which plans to gradually phase out the sUSD stablecoin and introduce significant reforms to the "debt amnesty" plan and the SNX staking mechanism.
The main contents include freezing sUSD on both the Ethereum mainnet and Optimism, halting transfers, minting, and burning, and taking a snapshot of holders. Eligible holders can exchange newly minted SNX at a ratio of 1 sUSD = 4 SNX (with a 1-year lock-up and 1-year linear release); the original sUSD staking ratio requirement will be cancelled, and the remaining debt will be moved into a new staking model (4-year lock-up plus 1-year linear release), with participants able to exit early by fully repaying their debt; staking will be decoupled from old sUSD obligations, and stakers will no longer need to hold or stake sUSD. Additionally, if the protocol generates more than 10 million USD in income within 2 years, 25% of that will be distributed to former sUSD holders in USDT (with specific parameters adjustable via SCCP).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
